Effect of intravenous iron on endogenous erythropoietin and FGF-23 secretion in patients with chronic kidney disease

References

• Cernaro V, Coppolino G, Visconti L, et al. Erythropoiesis and chronic kidney disease-related anemia: from physiology to new therapeutic advancements. Med Res Rev. 2019;39(2):427–460.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–1634.
   PubMed Web of Science ®Google Scholar
• Stivelman JC. Target-based anemia management with erythropoiesis stimulating agents (risks and benefits relearned) and iron (still more to learn). Semin Dial. 2017;30(2):142–148.
   PubMed Web of Science ®Google Scholar
• Ifie E, Oyibo SO, Joshi H, et al. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabetes Metab Case Rep. 2019;2019(1):19–0065.
   PubMedGoogle Scholar
• Suzuki N, Matsuo-Tezuka Y, Sasaki Y, et al. Iron attenuates erythropoietin production by decreasing hypoxia-inducible transcription factor 2α concentrations in renal interstitial fibroblasts. Kidney Int. 2018;94(5):900–911.
   PubMed Web of Science ®Google Scholar
• Muras-Szwedziak K, Nowicki M. Associations Between intravenous iron, inflammation and FGF23 in Non-Dialysis patients with chronic kidney disease stages 3-5. Kidney Blood Press Res. 2018;43(1):143–151.
   PubMed Web of Science ®Google Scholar
• Wheeler JA, Clinkenbeard EL. Regulation of fibroblast growth factor 23 by iron, EPO, and HIF. Curr Mol Biol Rep. 2019;5(1):8–17.
   PubMedGoogle Scholar
• Toro L, Barrientos V, León P, et al. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int. 2018;93(5):1131–1141.
   PubMed Web of Science ®Google Scholar
• Agoro R, Montagna A, Goetz R, et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. Faseb J. 2018;32(7):3752–3764.
   PubMed Web of Science ®Google Scholar
• van Vuren AJ, Gaillard CAJM, Eisenga MF, et al. The EPO-FGF23 signaling pathway in erythroid progenitor cells: opening a new area of research. Front Physiol. 2019;10:304.
   PubMed Web of Science ®Google Scholar
• Hiram-Bab S, Liron T, Deshet-Unger N, et al. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. Faseb J. 2015;29(5):1890–1900.
   PubMed Web of Science ®Google Scholar
• Coe LM, Madathil SV, Casu C, et al. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014;289(14):9795–9810.
   PubMed Web of Science ®Google Scholar
• Nam KH, Kim H, An SY, et al. Circulating fibroblast growth factor-23 levels are associated with an increased risk of anemia development in patients with nondialysis chronic kidney disease. Sci Rep. 2018;8(1):7294.
   PubMedGoogle Scholar
• David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135–146.
   PubMed Web of Science ®Google Scholar
• Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004;36(6):579–581.
   PubMed Web of Science ®Google Scholar
• Kato K, Jeanneau C, Tarp MA, et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem. 2006;281(27):18370–18377.
   PubMed Web of Science ®Google Scholar
• Smith ER, Cai MM, McMahon LP, et al. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012;97(9):3357–3365.
   PubMed Web of Science ®Google Scholar
• Takashi Y, Fukumoto S. FGF23-Klotho axis in CKD. Ren Replace Ther. 2016;2:5.
   Google Scholar
• Jelkmann W. Regulation of erythropoietin production. J Physiol. 2011;589(Pt 6):1251–1258.
   PubMed Web of Science ®Google Scholar
• Toblli JE, Angerosa M. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. Drug Des Devel Ther. 2014;8:2475–2491.
   PubMed Web of Science ®Google Scholar
• Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50.
   PubMed Web of Science ®Google Scholar
• Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793–1803.
   PubMed Web of Science ®Google Scholar
• Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675–468675.
   PubMed Web of Science ®Google Scholar
• Prats M, Font R, García C, et al. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study. BMC Nephrol. 2013;14:167.
   PubMed Web of Science ®Google Scholar
• Daryadel A, Bettoni C, Haider T, et al. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. Pflugers Arch. 2018;470(10):1569–1582.
   PubMed Web of Science ®Google Scholar
• Gravesen E, Hofman-Bang J, Mace ML, et al. High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. BMC Nephrol. 2013;14:281.
   PubMed Web of Science ®Google Scholar
• Clinkenbeard E, Hanudel M, Stayrook K, et al. Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica. 2017;102(11):e427–e430.
   PubMed Web of Science ®Google Scholar
• Hanudel MR, Eisenga MF, Rappaport M, et al. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant. 2019;34(12):2057–2065.
   PubMed Web of Science ®Google Scholar
• Hanudel MR, Chua K, Rappaport M, et al. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol. 2016;311:1369–1377.
   Web of Science ®Google Scholar
• Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013;27(1):41–53.
   PubMed Web of Science ®Google Scholar
• Vervloet M. Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol. 2019;15(2):109–120.
   PubMed Web of Science ®Google Scholar